Description

BSE revokes the suspension of trading in equity shares of Rekvina Laboratories Limited (Scrip Code: 526075), allowing normal trading to resume.

Summary

BSE has revoked the suspension of trading in equity shares of Rekvina Laboratories Limited (Scrip Code: 526075, ISIN: INE092O01028). The company, a pharmaceutical manufacturer focused on providing quality medication at affordable prices, is now permitted to resume normal trading activities on the Bombay Stock Exchange.

Key Points

  • Company Name: Rekvina Laboratories Limited
  • Scrip Code: 526075
  • ISIN: INE092O01028
  • Trading suspension has been revoked
  • Company operates in the pharmaceutical industry
  • Manufacturing facility located at GIDC Estate, Waghodia, Vadodara-391760
  • Registered office: 36-Sampatrao Colony, Alkapuri, Vadodara-390007
  • Managing Director: Amit Mukesh Shah (DIN: 01993211)
  • Company Secretary: Deepak Khandelwal
  • Current Auditor: M/s. Y.M. Shah & Co. (FRN: 114124W) for 2024-25 to 2028-29
  • Group Company: Radiant Parenterals Limited
  • Operational Status: Active

Company Profile

Business Nature: Pharmaceutical industry focused on providing quality medication at affordable prices to help reduce healthcare costs

Board of Directors:

  • Amit Mukesh Shah (Managing Director & Chairman)
  • Surbhit Mukesh Shah
  • Dhruvalkumar Patel
  • Chetanbhai Patel
  • Ilaben Pathak
  • Parteek Jain

Auditor Changes: The company changed auditors from M/s. Jigar Adhyaru & Co. (2019-20 to 2023-24) to M/s. Y.M. Shah & Co. (2024-25 to 2028-29) due to completion of statutory term by the previous auditor in compliance with regulatory requirements.

Regulatory Changes

Trading suspension previously imposed on Rekvina Laboratories Limited has been lifted, restoring normal trading status for the company’s equity shares on BSE.

Compliance Requirements

  • Company has confirmed payment of listing fees to BSE
  • Company maintains active operational status
  • No action taken by other exchanges in the last five years
  • Company website: https://rekvinalaboratories.in/

Important Dates

  • Circular Date: December 30, 2025
  • Effective Date: Trading suspension revoked as of this circular

Impact Assessment

Market Impact: Medium - The revocation allows shareholders of Rekvina Laboratories to resume trading their equity holdings. This is positive for existing shareholders who were unable to trade during the suspension period.

Operational Impact: Positive for the company as it restores market confidence and provides liquidity to shareholders. The company continues active pharmaceutical manufacturing operations at its Waghodia facility.

Investor Impact: Shareholders can now buy, sell, or trade equity shares of Rekvina Laboratories on BSE, restoring market liquidity for this security.

Impact Justification

Revocation of trading suspension for a single company allows shareholders to resume trading but has limited broader market impact